Nexstim Plc received an order for an NBS 6 system from a new clinic customer located in Florida, Unites States. Launched in 2023 in the United States and Europe, the NBS 6 is a new Nexstim product generation that brings the usability of the Nexstim system to a new level. The NBS 6 is currently FDA-approved for the treatment of major depressive disorder (MDD), as well as CE-marked for the treatment of MDD and chronic unilateral neuropathic pain.

Nexstim?s systems are based on the company?s unique navigated transcranial magnetic stimulation (nTMS) technology.